KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Inhaled Sedation in Acute Respiratory Distress Syndrome: The SESAR Randomized Clinical Trial.

Matthieu Jabaudon, Jean-Pierre Quenot, Julio Badie, Jules Audard, Samir Jaber, Benjamin Rieu, Caroline Varillon, Antoine Monsel, François Thouy, Julien Lorber, Joël Cousson, Stéphanie Bulyez, Jérémy Bourenne, Ghada Sboui, Claire Lhommet, Virginie Lemiale, Belaïd Bouhemad, Clément Brault, Sigismond Lasocki, François Legay, Thomas Lebouvier, Arthur Durand, Julien Pottecher, Alexandre Conia, Delphine Brégeaud, Lionel Velly, Arnaud W Thille, Fabien Lambiotte, Erwan L'Her, Mehran Monchi, Antoine Roquilly, Aziz Berrouba, Franck Verdonk, Russell Chabanne, Thomas Godet, Marc Garnier, Raiko Blondonnet, Jérémy Vernhes, Vincent Sapin, Lucile Borao, Emmanuel Futier, Bruno Pereira, Jean-Michel Constantin, SESAR Trial Investigators

JAMA 333(18) 1608-1617

PMID40098564
PMCIDPMC11920880
DOI10.1001/jama.2025.3169
发表日期2025-03-18
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

IMPORTANCE: Whether the use of inhaled or intravenous sedation affects outcomes differentially in mechanically ventilated adults with acute respiratory distress syndrome (ARDS) is unknown. OBJECTIVE: To determine the efficacy and safety of inhaled sevoflurane compared with intravenous propofol for sedation in patients with ARDS. DESIGN, SETTING, AND PARTICIPANTS: Phase 3 randomized, open-label, assessor-blinded clinical trial conducted from May 2020 to October 2023 with 90-day follow-up. Adults with early moderate to severe ARDS (defined by a ratio of Pao2 to the fraction of inspired oxygen of <150 mm Hg with a positive end-expiratory pressure of ≥8 cm H2O) were enrolled in 37 French intensive care units. INTERVENTIONS: Patients were randomized to a strategy of inhaled sedation with sevoflurane (intervention group) or to a strategy of intravenous sedation with propofol (control group) for up to 7 days. MAIN OUTCOMES AND MEASURES: The primary end point was the number of ventilator-free days at 28 days; the key secondary end point was 90-day survival. RESULTS: Of 687 patients enrolled (mean [SD] age, 65 [12] years; 30% female), 346 were randomized to sevoflurane and 341 to propofol. The median total duration of sedation was 7 days (IQR, 4 to 7) in both groups. The number of ventilator-free days through day 28 was 0.0 days (IQR, 0.0 to 11.9) in the sevoflurane group and 0.0 days (IQR, 0.0 to 18.7) in the propofol group (median difference, -2.1 [95% CI, -3.6 to -0.7]; standardized hazard ratio, 0.76 [95% CI, 0.50 to 0.97]). The 90-day survival rates were 47.1% and 55.7% in the sevoflurane and propofol groups, respectively (hazard ratio, 1.31 [95% CI, 1.05 to 1.62]). Among 4 secondary outcomes, sevoflurane was associated with higher 7-day mortality (19.4% vs 13.5%, respectively; relative risk, 1.44 [95% CI, 1.02 to 2.03]) and fewer intensive care unit-free days through day 28 (median, 0.0 [IQR, 0.0 to 6.0] vs 0.0 [IQR, 0.0 to 15.0]; median difference, -2.5 [95% CI, -3.7 to -1.4]) compared with propofol. CONCLUSIONS AND RELEVANCE: Among patients with moderate to severe ARDS, inhaled sedation with sevoflurane resulted in fewer ventilator-free days at day 28 and lower 90-day survival than sedation with propofol. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04235608.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2

Figure 2.. Kaplan-Meier Estimates of 90-Day Survival in the Modified Intention-to-Treat Population At 90 days, 183 of 346 patients (52.9%) in the sevoflurane group and 151 of 341 patients (44.3%) in the propofol group had died. The median follow-up times were 40.5 days (IQR, 10.0-90.0) in the sevoflurane group and 90.0 days (IQR, 14.0-90.0) in the propofol group.

Kaplan-Meier_Estimates_of_90-Day_Survival

90-Day Survival

Figure 2 · Panel Kaplan-Meier_Estimates_of_90-Day_Survival

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Kaplan-Meier_Estimates_of_90-Day_Survival 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:short span曲线 1:frequent upward jumps曲线 1:off origin start
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Patient Screening, Enrollment, and Follow-Up in the Sevoflurane for Sedation in ARDS (SESAR) Trial CPAP/BIPAP indicates continuous positive airway pressure/bilevel positive airway pressure; ECMO, extracorporeal membraine oxygenation; and F i o 2 , fraction of inspired oxygen. a Each patient could have more than 1 reason for exclusion. b Reasons included unknown reason (n = 22), clinical deterioration (n = 8), ventilation or sedation deemed difficult (n = 3), pneumothorax (n = 2), low fraction of inspired oxygen (n = 2), and lung ventilation (n = 1). c Included all patients who underwent randomization except those who withdrew consent or were under judicial protection. d Each patient could have more than 1 protocol violation.
非 KM Figure
Figure 3Figure 3.. Cumulative Numbers of Patients Dead, Extubated (Alive), and Discharged (Alive) From the Intensive Care Unit From Randomization Through Day 28 in the Modified Intention-to-Treat Population Extubation (alive) was counted as the end of the last period of assisted breathing to day 28. ICU indicates intensive care unit.
非 KM Figure